A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.

CONCLUSIONS: In comparison to patients aged 61 to 69 years, those aged ≥70 years have poorer survival. Prolonged survival is obtainable with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-like in elderly Chinese patients in all age groups, indicating that the R-CHOP-like regimen should be considered for this population, even for those aged 70 years or older.
PMID: 31335477 [PubMed - as supplied by publisher]

Source: Chinese Medical Journal - July 21, 2019 Category: General Medicine Authors: Liu P, Han Y, Jiang SY, He XH, Qin Y, Gui L, Zhou SY, Zhou LQ, Yang JL, Yang S, Wen TY, Shi YK Tags: Chin Med J (Engl) Source Type: research